GSK, Genmab Set “Ambitious” Development Plan For HuMax-CD20

GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet